Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-18T17:27:17.971Z Has data issue: false hasContentIssue false
  • English
  • Français

Poliomyelitis in the Netherlands before and after vaccination with inactivated poliovaccine

Published online by Cambridge University Press:  15 May 2009

B. Hofman
B. Hofman
Affiliation:
Rijks Instituut voor de Volksgezondheid, Sterrenbos 1, Utrecht, The Netherlands
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Formalin-inactivated polio vaccine has been used in the Netherlands since 1957. Within 3 years all children born in 1945 and later were offered vaccine. In the first years poliovaccine from different manufacturers were used. In 1961 a vaccine produced in the Netherlands by the ‘Rijks Instituut voor de Volksgezondheid’ (National Institute of Public Health) became available and in 1962 the poliomyelitis components were incorporated in a quadruple vaccine, which contains 15 Lf diphtheria, 5 Lf tetanus toxoid and 16 × 109Bordetella pertussis organisms in addition to the three polio components. As an adjuvant this quadruple vaccine contains 1·5 mg. aluminium phosphate per 1 ml. dose. For infants the schedule became three doses at ages 3, 4 and 5 months respectively, followed by a booster dose at the end of the first year. The over-all acceptance rate can be estimated at almost 90% of those eligible, but there were pockets in the population with lower rates.

Since 1924 poliomyelitis has been a notifiable disease. During and after the last World War major epidemics occurred.

The poliomyelitis morbidity rates in the 8 post-vaccination years 1958–65 were compared with those from two preceding 4-year periods 1950–3 and 1954–7. In the 1–4-year-old children, who presented the most vulnerable age group, paralytic poliomyelitis was reduced by about 97 % and in the other age groups this percentage was slightly less. The over-all reduction was 96 %. Comparison of the morbidity rates of non-vaccinated persons in 1958–65 with the rates from 1950–3 and 1954–7 gave an impression of the extent of the herd immunity. These rates were reduced 70–80 % in the children under 15 years and 90–95 % in those over this age. The individual protection given to the vaccinated was calculated from the morbidity rates in non-vaccinated, incompletely and fully vaccinated persons in the 1958–65 period. The reduction of morbidity was 90–95% for children of 1–14 years who got three doses or more and about 85 % for those who had only 1 or 2 doses. Fully vaccinated children, who are profiting from both individual protection and herd immunity, showed a reduction of 97–99 %.

From the data presented it is concluded that vaccination with inactivated poliomyelitis vaccine can provide very effective protection for the individual and the community provided that a vaccine of good quality is used and the rate of acceptance is 75 % or better.

Type
Research Article
Information
Journal of Hygiene , Volume 65 , Issue 4 , December 1967 , pp. 547 - 557
Copyright
Copyright © Cambridge University Press 1967

References

REFERENCES

Brandwijk, A. C., Cohen, H., Hekker, A. C., Hofman, B., Van Ramshorst, J. D., Tasman, A., Van Driel, C. B., Schaapman-Tilma, B. & De Vries, J. A. (1961). Een gecombineerd difterie–kinkhoest–tetanus–poliomyelitis vaccin (DKTP) ter immunisatie van de zuigeling. Ned. Tijdschr. Geneesk 105, 1331.Google Scholar
Centraal Bureau Voor De Statistiek (1953–1965). Maandstatistiek van de bevolking en de Volksgezondheid. Ed. de Haan-Utrecht, .Google Scholar
Centraal Bureau Voor De Statistiek (1963). Bevolking van Nederland. Leeftijd en geslacht 1900–1952. Ed. de Haan-Utrecht, .Google Scholar
Dick, G. W. A., Dane, D. S., McAlister, J., Briggs, M., Nelson, R. & Field, C. M. B. (1961). Vaccination against poliomyelitis with live virus vaccines. 7. Effect of previous Salk vaccination on virus excretion. Br. med. J. ii, 266.CrossRefGoogle Scholar
Duxbury, A. E., Goulding, G. & Graydon, J. J. (1963). Vaccination against poliomyelitis; The present position in Australia. Lancet i, 377.CrossRefGoogle Scholar
Francis, T. Jr, Korns, R. F., Voight, R. B., Boisen, M., Hemphill, F. M., Napier, J. A. & Tolchinsky, E. (1955). An evaluation of the 1954 poliomyelitis vaccine trials. Summary report. Am. J. publ. Hth 45, part 2 (suppl).Google Scholar
Gard, S. (1964). Polio virus vaccination and epidemiologic situation in Scandinavia. Proc. Xth Symposium Europ. Ass. Poliomyelitis and Allied Diseases. Warsaw.Google Scholar
Gard, S. (1966). Aspects of polio virus epidemiology and surveillance in Sweden. Proc. XIth Symposium Europ. Ass. Poliomyelitis and Allied Diseases, Rome. (In preparation.)Google Scholar
Henry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson, A. J. H., Mason, P. J., Barnes, J. M. & Beale, A. J. (1966). A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J. Hyg., Camb. 64, 105.CrossRefGoogle ScholarPubMed
Kubryk, D. (1960). Paralytic poliomyelitis in Canada, 1959. Can. J. publ. Hlth 51, 389.Google Scholar
Langmuir, A. D. (1960). Inactivated virus vaccines: protective efficacy. Int. Polio Conf. no. 5. Copenhagen 1960.Google Scholar
Olin, G. (1960). Protective efficacy of inactivated polio virus vaccines: Swedish experiences. Int. Polio. Conf. no. 5. Copenhagen, 1960.Google Scholar
Perkins, F. T., Yetts, R. & Gaisford, W. (1958). Serological response of infants to poliomyelitis vaccine. Br. med. J. ii, 68.CrossRefGoogle Scholar
Perkins, F. T., Yetts, R. & Gaisford, W. (1959). Response of infants to a third dose of poliomyelitis vaccine given 10 to 12 months after primary immunization. Br. med. J. i, 680.CrossRefGoogle Scholar